18 Oct Global Health Limited Announces September 2024 Quarterly Business Report
Result highlights include:
- Annual Recurring Revenue up 13% on PCP
- Cash receipts up 13% on the Previous Corresponding Period (PCP)
- Net Operating and Investing cashflow reduced by 14% from PCP
- Group Cashflow deficit reduced by 28% from PCP
Global Health Limited (ASX: GLH) (“Global Health” or “the Group”) is pleased to release its Appendix 4C Cash Flow Report for the quarter ended 30 September 2024 (Q1 FY25), and the accompanying Quarterly Business Activity Report. The financial performance commentary for Q1 FY25 Quarter is relative to the Previous Corresponding Period (PCP) being Q1 FY24 (Jul- 23 to Sep-23). From 1 July 2023 all R&D expenditure is expensed.
Financial Commentary
- Annual Recurring Revenue (ARR) up 13% on PCP to $1.7M
- The Company’s ARR in Q1 FY25 was $1.71M which was an 11.62% increase on the June Qtr. (Q4 FY24) and a 13% increase on the PCP.
- ARR for FY25 is tracking to $7M ARR for the 12 months to June-25.
- Cash receipts up 13% on Previous Corresponding Period (PCP)
- Net Operating and Investing cashflow reduced by 14% from PCP
- Group Cashflow deficit reduced by 28% from PCP
See full report here: September 2024 Quarterly Business Activity Report & Appendix 4
This ASX announcement has been authorised by the Board of Global Health Limited (ASX:GLH).
For further information, please visit the ASX website here.